Anti-Anxiety Medications with No Known Effect on Hearing
SSRIs (selective serotonin reuptake inhibitors) are the recommended first-line anti-anxiety medications and have no established direct ototoxic effects on hearing. Specifically, escitalopram, sertraline, fluvoxamine, and paroxetine are suggested as primary treatment options 1.
Primary Recommendations
First-Line Agents (SSRIs)
The following SSRIs are recommended for anxiety disorders and do not cause hearing loss as a direct medication effect 1:
- Escitalopram (Lexapro)
- Sertraline (Zoloft)
- Fluvoxamine (Luvox)
- Paroxetine (Paxil)
Second-Line Agents (SNRIs)
If SSRIs are ineffective or not tolerated 1:
- Venlafaxine (Effexor)
- Duloxetine (Cymbalta)
These medications work through serotonin and norepinephrine reuptake inhibition and have no documented ototoxic properties 2.
Critical Evidence Regarding Hearing
Important Nuance: Antidepressants and Hearing Loss Association
While SSRIs and SNRIs are not directly ototoxic, one large population-based study found an association between antidepressant use and increased risk of sudden sensorineural hearing loss (SSNHL), with an adjusted hazard ratio of 1.36 3. This risk increased with the number of antidepressant classes used concurrently (HR 2.05 for four classes) 3.
However, this association does not establish causation and may reflect:
- Underlying anxiety/depression pathophysiology affecting hearing
- Confounding by indication (patients with anxiety may have other risk factors)
- The study found ALL classes increased risk similarly, suggesting a non-pharmacologic mechanism 3
Counterbalancing Evidence
Interestingly, fluoxetine and fluvoxamine may actually protect against cisplatin-induced ototoxicity (HR 0.62), suggesting certain SSRIs might have otoprotective properties in specific contexts 4.
Medications to AVOID for Hearing Concerns
The following anti-anxiety agents have documented ototoxic potential 5:
- Benzodiazepines: While not directly ototoxic, they are mentioned in guidelines but lack strong evidence for anxiety disorders and carry dependency risks 1
- Beta blockers (atenolol, propranolol): Specifically deprecated by Canadian guidelines and have potential auditory effects 1
Practical Implementation Algorithm
Step 1: Start with an SSRI from the first-line agents listed above
- Begin with escitalopram or sertraline (preferred in international guidelines) 1
- Monitor for common side effects: nausea, somnolence, dizziness 1
Step 2: If inadequate response after adequate trial (typically 8-12 weeks at therapeutic dose)
- Switch to another SSRI, OR
- Consider SNRI (venlafaxine or duloxetine) 1
Step 3: Monitor for serious but rare adverse effects
- Serotonin syndrome
- Behavioral activation/suicidal ideation (especially age <24 years)
- Abnormal bleeding
- Sexual dysfunction 2
Common Pitfalls to Avoid
Do not use multiple antidepressant classes concurrently if hearing preservation is a priority, as this increases SSNHL risk 3
Avoid beta blockers (atenolol, propranolol) as they are specifically not recommended for anxiety disorders and may affect hearing 1
Do not assume benzodiazepines are safer - while they may work acutely, they lack evidence for long-term anxiety treatment and carry significant dependency risks 1
Monitor blood pressure with SNRIs as they can cause sustained hypertension, which itself may affect cochlear blood flow 2
Bottom Line
SSRIs remain the safest anti-anxiety medications regarding hearing, with no direct ototoxic mechanism. The population-level association with SSNHL appears related to the underlying condition rather than the medication itself, and some SSRIs may even be otoprotective 4, 3. Choose escitalopram or sertraline as first-line agents, avoid concurrent use of multiple antidepressant classes, and monitor hearing if patients report auditory symptoms 1.